Encellin
San Francisco, US · Founded 2015 · Delaware corporation · 7 employees on LinkedIn · 8 known investors
Encellin develops next-generation therapies for patients with chronic unmet clinical needs, using technology originating from Dr. Tejal Desai's laboratory at UCSF that combines micro and nanotechnologies with novel drug delivery approaches. The company focuses on therapeutic delivery platforms and cell-based treatments, particularly for diseases including diabetes and autoimmune conditions.
Founders & leadership
Encellin was founded in 2015 by Tejal Desai, Ronald Martell, Crystal Nyitray, and Grace Wei.
Board
Investors · 8
Reported raises · per SEC filings
Form D private placements$12M disclosed across 2 of 3 rounds · 2019–2025
▶$9.9MraisedDec 2023 · 26 investors · OtherRule 506(b)
- Crystal NyitrayExecutive Officer, Director
- Maria del Consuelo ValverdeDirector
- Grace WeiDirector
- Offering amount
- $9.9M
- Amount sold
- $9.9M
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedJul 2019 · 7 investors · OtherRule 506(b)
- Crystal NyitrayExecutive Officer, Director, Promoter
- Grace WeiExecutive Officer, Director, Promoter
- Ronald MartellExecutive Officer, Director
- Maria del Consuelo ValverdeDirector
- Offering amount
- $2.7M
- Amount sold
- $2.1M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Encellin is a San Francisco-based biotechnology company developing Encapsulated Cell Replacement Therapy (ENCRT), a minimally invasive implant designed to house living cells inside the body so they can survive and release therapeutics as needed. The approach combines a cell encapsulation technology with functional cell therapies, positioning enclosed cells as self-regulating producers of therapeutic molecules for chronic disease.
The company's initial pipeline targets endocrine disorders with a clear mechanism of action. Its lead programs address hypoglycemia in type 1 diabetes, which the company describes as the highest unmet clinical need in that indication. The stated platform goal is to deliver sustained therapy over years from a single implant.
Traction
The company has reported interim clinical results from a cell therapy trial, describing early evidence of non-fibrotic engraftment and viable encapsulated human islets in type 1 diabetes subjects, and has raised financing to advance its type 1 diabetes program.
Latest developments
Encellin announced interim clinical results indicating first-in-human non-fibrotic engraftment and viable encapsulated human islets in subjects with type 1 diabetes, coverage of early trial results from Breakthrough T1D, and an approximately $10 million financing for its type 1 diabetes cell replacement therapy.
▸Full profile — market position, technology, go-to-market, geography
Market position
Encellin operates in cell replacement and encapsulated cell therapy for endocrine disease, with early clinical-stage data in type 1 diabetes.
Technology
ENCRT is an implantable cell encapsulation device intended to keep enclosed cells viable in the body while allowing them to function as molecular factories that release therapeutics on demand. The company reports interim clinical results describing first-in-human non-fibrotic engraftment and viable encapsulated human islets in subjects with type 1 diabetes.
Go-to-market
Patients with chronic endocrine disorders, initially people with type 1 diabetes who experience hypoglycemia.
Geography
Headquartered in San Francisco, United States.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 1
by search overlap
Companies competing with Encellin for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 2
launches, deals, and filingsEndpoints reported that Encellin raised approximately $10 million to advance its type 1 diabetes cell replacement therapy.
$10M source ↗
Encellin announced interim clinical results showing first-in-human non-fibrotic engraftment and viable encapsulated human islets in subjects with type 1 diabetes.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- Encellinencellin.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Encellin do?
- Encellin develops an encapsulated cell replacement therapy implant for endocrine disorders, starting with type 1 diabetes.
- Who founded Encellin?
- Encellin was founded by Tejal Desai, Ronald Martell, Crystal Nyitray, Grace Wei in 2015.
- Who are Encellin's investors?
- Encellin's investors include Evolution VC Partners, How Women Invest, ITERATIVE, Metaplanet, BoxOne Ventures, Khosla Ventures, SV Latam Capital, SVLC.
- How much funding has Encellin raised?
- Encellin has disclosed $12M raised across 2 of its 3 known rounds.
- Where is Encellin headquartered?
- Encellin is headquartered in San Francisco, US.